A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP CLINICAL TRIAL OF NIPOCALIMAB IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (SPIREA): STUDY DESIGN

被引：0

作者：

Najem, C. E. ^{[1
]}

Craig, J. ^{[1
]}

Stine, L. Christopher ^{[2
]}

Zazzetti, F. ^{[3
]}

Shu, C. ^{[4
]}

Noel, W. ^{[5
]}

Blango Sr, C. ^{[1
]}

Karyekar, C. S. ^{[1
]}

Aggarwal, R. ^{[6
]}

机构：

[1] Janssen Pharmaceut Co Johnson & Johnson, Spring House, PA USA

[2] Johns Hopkins Sch Med, Med & Neurol, Baltimore, MD USA

[3] Janssen Med Affairs Global Serv LLC, Buenos Aires, Argentina

[4] Janssen Res & Dev LLC, Spring House, PA USA

[5] Janssen Pharmaceut, Vilvoorde, Belgium

[6] Univ Pittsburgh, Dept Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA

来源：

关键词：

Targeted synthetic drugs; Randomized controlled trial; Autoantibodies; Glucocorticoids; Disease-modifying Drugs (DMARDs);

D O I：

10.1136/annrheumdis-2024-eular.3020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0250

引用

页数：2